Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

RXST Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against RxSight, Inc.

By: Robbins LLP via GlobeNewswire

July 25, 2025 at 15:26 PM EDT

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) --

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025. RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses (“LAL”) used in cataract surgery in the United States. The Company’s primary product is the RxSight system, which includes the LAL and a specially designed machine for delivering light to the eye, the Light Delivery Device (“LDD”).

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that RxSight, Inc. (RXST) Misled Investors Regarding Demand for its Products

According to the complaint, during the class period, defendants failed to disclose to investors that: (1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight’s products; and (3) as a result, RxSight was unlikely to meet its own previously issued finanical guidance for fiscal year 2025.

On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, and LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company’s Chief Executive Officer, Ronald Kurtz, disclosed that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.” On this news, RxSight’s stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.

What Now: You may be eligible to participate in the class action against RxSight, Inc. Shareholders who want to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against RxSight, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/